By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


immatics biotechnologies GmbH 

Paul-Ehrlich-Strasse 15

Tuebingen    D-72076  Germany
Phone: 49-7071-565125-0 Fax: 49-7071-565125-99


Company News
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014 10:58:43 AM
immatics biotechnologies GmbH Reels In €22 Million Series D 7/16/2014 6:22:49 AM
Promising Results In Phase 1 Trial Lead immatics biotechnologies GmbH To Continue Work On Vaccine (IMA950) For Glioblastoma 4/23/2014 12:53:51 PM
immatics biotechnologies GmbH, Roche (RHHBY) Ink Cancer Pact Worth Up To $1 Billion 11/13/2013 6:27:11 AM
immatics biotechnologies GmbH Snags $46 Million in Series D Financing Round 10/15/2013 7:58:29 AM
immatics biotechnologies GmbH to Present at CIMT Annual Meeting 2013 in Mainz, Germany 5/13/2013 10:16:12 AM
immatics biotechnologies GmbH' CSO to Present in Major Symposium at 2013 American Association for Cancer Research Annual Meeting in Washington D.C. 4/4/2013 9:55:34 AM
immatics biotechnologies GmbH's Co-Founder Professor Dr Hans-Georg Rammensee Awarded the Bayer AG (BAY.F) Hansen Family Award 2013 3/7/2013 10:59:44 AM
immatics biotechnologies GmbH Appoints Peter Chambre as Chairman 11/12/2012 1:10:08 PM
immatics biotechnologies GmbH's Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment and is Granted U.S. Orphan Drug Designation by the FDA 11/8/2012 2:26:58 PM